The stock of Firefly Neuroscience Inc (AIFF) has gone up by 67.63% for the week, with a -66.17% drop in the past month and a 74.92% rise in the past quarter. The volatility ratio for the week is 22.60%, and the volatility levels for the past 30 days are 22.02% for AIFF. The simple moving average for the last 20 days is 2.98% for AIFF’s stock, with a simple moving average of 14.08% for the last 200 days.
Is It Worth Investing in Firefly Neuroscience Inc (NASDAQ: AIFF) Right Now?
Company’s 36-month beta value is 3.23.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AIFF is 3.30M, and currently, short sellers hold a 13.54% ratio of that floaft. The average trading volume of AIFF on March 18, 2025 was 8.74M shares.
AIFF) stock’s latest price update
Firefly Neuroscience Inc (NASDAQ: AIFF)’s stock price has soared by 23.06 in relation to previous closing price of 4.25. Nevertheless, the company has seen a gain of 67.63% in its stock price over the last five trading days. newsfilecorp.com reported 2025-03-06 that A growing body of clinical evidence supports the use of Firefly’s FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta–(Newsfile Corp. – March 6, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or “HEM”), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) (“Firefly”), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Hemostemix and Firefly will study brain wave activity in up to 100 patients before and after treatment with ACP-01 at baseline, 3-months, and 6-months post-treatment (the “Phase 1”).
AIFF Trading at 13.18% from the 50-Day Moving Average
After a stumble in the market that brought AIFF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.59% of loss for the given period.
Volatility was left at 22.02%, however, over the last 30 days, the volatility rate increased by 22.60%, as shares sank -41.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +97.36% upper at present.
During the last 5 trading sessions, AIFF rose by +67.63%, which changed the moving average for the period of 200-days by -31.09% in comparison to the 20-day moving average, which settled at $5.08. In addition, Firefly Neuroscience Inc saw 97.36% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AIFF
Equity return is now at value -66.59, with -24.58 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.05.
Conclusion
In a nutshell, Firefly Neuroscience Inc (AIFF) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
